Lyfegen, a Basel, Switzerland-based drug rebate management technology company, raised additional CHF5M in Series A funding.
The round was led by TX Ventures with additional participation from aMoon, and other investors.
The company intends to use the funds to accelerate its global expansion and innovation efforts, with a focus on extending its reach beyond Europe into new markets worldwide.
Led by CEO Girisha Fernando, Lyfegen is an independent provider of rebate management software designed for the healthcare industry. Its solutions are used by health insurances, governments, hospital payers, and pharmaceutical companies around the globe to reduce the administrative burden of managing complex drug pricing agreements and to optimize rebates and get better value from those agreements.
Today, 50+ healthcare organizations across 8 geographical markets use its solutions to streamline 4,000+ rebate agreements while tracking over $1 Billion in pharmaceutical revenue and managing over $0.5 Billion in rebates annually. These solutions enable healthcare organizations to improve pricing strategies, accelerate access to modern treatments, and better manage rebate complexities.
FinSMEs
11/12/2024